On April 3, 2026, Wohua Pharmaceutical officially launched the new packaging for its exclusive patented product, Shenzhiling Oral Liquid. The first batch rolled off the production line in Weifang, Shandong, marking a significant milestone for the national market.
This brand upgrade follows the strategic cooperation between Wohua Pharmaceutical and Beijing Yicongran Technology in November 2025. Consequently, it represents a substantial achievement in their joint brand-building efforts.
Shenzhiling Oral Liquid: A TCM Breakthrough
Alzheimer’s disease is often called the “fourth major killer” of elderly health. Shenzhiling Oral Liquidstands out as the only approved pure Traditional Chinese Medicine (TCM) preparation for this condition in China. Specifically, it fills a gap in the treatment of Alzheimer’s with Chinese patent medicine.
The product originates from classic TCM theories. It consists of ten medicinal herbs, including Dangshen, Guizhi, and Fuling. Professor Lin Shuimiao’s team at the Shanghai Institute of Geriatric Medicine spent over 20 years developing this formula. Furthermore, it has received support from national science and technology plans and holds 5 national invention patents. It is recommended by authoritative guidelines such as the *Clinical Practice Guideline for Alzheimer’s Disease*.
Clinical Efficacy and Safety
Clinical studies confirm that Shenzhiling Oral Liquid achieves multi-target intervention based on various pathological hypotheses of Alzheimer’s. Therefore, it effectively delays disease progression.As a pure plant-based formula, it offers high safety and is suitable for long-term patient use. This provides a unique solution for the comprehensive management of Alzheimer’s. You can learn more about TCM treatments in our Health & Medical Insights section.
Brand Renewal and Visual Upgrade
The packaging upgrade is a key milestone in the product’s brand construction. The new design integrates TCM cultural elements with modern aesthetics. It features a yellow “Forget-me-not” flower, which symbolizes “eternal memory.” Moreover, this design aligns perfectly with the product’s core value of “guarding memory.” The new image aims to enhance competitiveness in the terminal market through professional and emotional visual language.
Strong Financial Backing
Wohua Pharmaceutical’s excellent 2025 annual report provides strong support for this brand upgrade. According to the report, the company achieved a revenue of 817 million yuan. Remarkably, the net profit increased by 162.93% year-on-year, reaching a ten-year high. This robust financial performance ensures sufficient resources for R&D and market expansion. For more corporate details, you can visit the Wohua Pharmaceutical official website.
Future Prospects
With the acceleration of China’s aging population, Alzheimer’s prevention is shifting towards “early intervention and TCM integration.” Shenzhiling Oral Liquid holds broad market prospects due to its advantages in safety and early intervention. In the future, Wohua Pharmaceutical will continue to deepen cooperation to benefit more patients with this “Chinese solution.”
